Details of the Drug
General Information of Drug (ID: DM74RMP)
Drug Name |
1-phenyl-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-Phenylisatin; 723-89-7; 1-Phenylindoline-2,3-dione; 1-Phenyl-1H-indole-2,3-dione; 1-phenylindole-2,3-dione; 1H-Indole-2,3-dione, 1-phenyl-; 1-Phenyl-indole-2,3-dione; INDOLE-2,3-DIONE, 1-PHENYL-; NSC 100013; BRN 0164531; 1H-Indole-2,3-dione, 1-phenyl- (9CI); 1-phenyl-2,3-dihydro-1H-indole-2,3-dione; UWCPWBIMRYXUOU-UHFFFAOYSA-N; AE-641/30401023; N-Phenylisatin; SMR000131753; phenylisatin; phenylindoledione; Phenyl Isatin; N-phenyl isatin; 1-phenyl isatin; NSC100013; 1-Phenylisatin,98%; 1-Phenylisatin, 97%; Isatin-based compound,
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 223.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||